IMGS-001

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameIMGS-001
Drug Alias NameIMGS-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed death-ligand 1 blockers +[4] 
TargetsProgrammed death-ligand 1Programmed death-ligand 2
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBostonGene CorpThe University Of Texas MD Anderson Cancer CenterImmunoGenesis Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A